Cargando…

Predictive factors for the outcomes of Graves’ disease patients with radioactive iodine ((131)I) treatment

Although radioactive iodine ((131)I) treatment (RIT) is recommended as the preferred option for patients with Graves’ disease (GD), the predictive factors for its clinical outcomes are still unclear. In the present study, we aim to investigate the factors influencing the success rate of RIT treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xing, Yu-Zhuo, Zhang, Kun, Jin, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2020
Materias:	Biotechnology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944668/ https://www.ncbi.nlm.nih.gov/pubmed/31840740 http://dx.doi.org/10.1042/BSR20191609

Ejemplares similares

Efficacy of radioactive iodine treatment of graves’ hyperthyroidism using a single calculated (131)I dose
por: Wong, Ka Kit, et al.
Publicado: (2018)

Outcomes of Radioactive Iodine ((131)I) Therapy among Hyperthyroid patients
por: Khan, Muhammad Sajjad Ali, et al.
Publicado: (2023)

Factors Predicting Treatment Failure in Patients Treated with Iodine-131 for Graves’ Disease
por: Manohar, Kuruva, et al.
Publicado: (2013)

Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves’ Disease
por: Kim, Min Joo, et al.
Publicado: (2022)

Risk factors of hepatic dysfunction in patients with Graves’ hyperthyroidism and the efficacy of (131)iodine treatment
por: Wang, Renfei, et al.
Publicado: (2017)

Transient cytotoxicity of (131)I beta radiation in hyperthyroid patients treated with radioactive iodine
por: Sundaram, P. Shanmuga, et al.
Publicado: (2011)

Effect of liver dysfunction on outcome of radioactive iodine therapy for Graves’ disease
por: Ze, Yuyang, et al.
Publicado: (2022)

Therapeutic applications of radioactive (131)iodine: Procedures and incidents with capsules
por: Al Aamri, Marwa, et al.
Publicado: (2016)

Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves’ disease patients
por: Hu, Rui-Ting, et al.
Publicado: (2020)

DIFFERENTIATED THYROID CANCER IN PEDIATRIC POPULATION (≤18 YEARS): POSTOPERATIVE TREATMENT WITH RADIOACTIVE IODINE (I-131)
por: Prpić, Marin, et al.
Publicado: (2019)

Incidence of Hypothyreoidism after Radioactive Iodine–I131 Treatment in Dependance of Hyperthyreoidism Etiology and Therapy Dose
por: Beslic, Nermina, et al.
Publicado: (2017)

Probiotic Bacteria Cannot Mitigate the Adverse Effects of Radioactive Iodine-131 Treatment
por: Mortazavi, Seyed Mohammad Javad, et al.
Publicado: (2023)

The Incidence of Hypothyroidism Following the Radioactive Iodine Treatment of Graves’ Disease and the Predictive Factors Influencing its Development
por: Husseni, Maha Abd El-Kareem El-Sayed
Publicado: (2016)

Clinical experience with radioactive iodine in the treatment of childhood and adolescent Graves' disease
por: Cury, Adriano N, et al.
Publicado: (2012)

SAT469 Risk Factors for Relapse in Graves’ Disease and the Clinical Outcomes of Radioactive Iodine Treatment in Relapsed Cases
por: WingChing, Li, et al.
Publicado: (2023)

Change in BMI after radioactive iodine ablation for graves disease
por: Chen, Melinda, et al.
Publicado: (2017)

Iodine-131 induced hepatotoxicity in previously healthy patients with Grave’s disease
por: Jhummon, Navina Priya, et al.
Publicado: (2013)

Acute psychosis caused by hypothyroidism following radioactive iodine treatment of Graves' disease
por: Hyams, Catherine, et al.
Publicado: (2013)

Treatment of Graves’ Disease With a Combination of Low Iodine Diet and Potassium Iodide Plus Radioactive Iodine Treatment
por: Ebrahim, Ismail, et al.
Publicado: (2021)

Chylothorax Associated with Substernal Goiter in Graves’ Disease Treated with Radioactive Iodine
por: Young Oh, Seo, et al.
Publicado: (2017)

LBODP096 High Failure Rate Of Radioactive Iodine-131 (Rai) Therapy For The Treatment Of Grave's Disease And Toxic Multinodular Goiter In An Urban Municipal Hospital Clinic
por: Handoo, Maryam Manzoor, et al.
Publicado: (2022)

Follow-up and evaluation of the pregnancy outcome in women of reproductive age with Graves’ disease after (131)Iodine treatment
por: Zhang, Li-Hua, et al.
Publicado: (2016)

Dependence of radioactive iodine-131 capture by the lacrimal ducts on the tear production level
por: Yartsev, Vasily D, et al.
Publicado: (2023)

Anaplastic Thyroid Carcinoma Following Radioactive Iodine Therapy for Graves' Disease
por: Kim, Sun Hwa, et al.
Publicado: (2013)

Graves' Disease-Related Pancytopenia Improved after Radioactive Iodine Ablation
por: Hamid, Omnia A., et al.
Publicado: (2020)

Association between radioactive iodine uptake and neutropenia in untreated Graves’ disease
por: Yang, Qian, et al.
Publicado: (2023)

Estimation of effective half life of clearance of radioactive Iodine ((131)I) in patients treated for hyperthyroidism and carcinoma thyroid
por: Ravichandran, R, et al.
Publicado: (2010)

(131)I thyroid activity and committed dose assessment among family members of patients treated with radioactive iodine
por: Brudecki, K., et al.
Publicado: (2020)

Age moderates the associations between TRAbs, free T3 and outcomes of Graves’ disease patients with radioactive iodine treatment
por: Lu, Lusi, et al.
Publicado: (2020)

Thyroid Isthmus Length and Iodine Turnover as Predictors of Successful Radioactive Iodine Therapy in Patients with Graves' Disease
por: Park, Se Hee, et al.
Publicado: (2017)

Radioactive Body Burden Measurements in (131)Iodine Therapy for Differentiated Thyroid Cancer: Effect of Recombinant Thyroid Stimulating Hormone in Whole Body (131)Iodine Clearance
por: Ravichandran, Ramamoorthy, et al.
Publicado: (2014)

Determination of administered activities for the treatment of Graves' disease with iodine-131: Proposition of a simplified dosimetric procedure
por: Soli, Idrissa Adamou, et al.
Publicado: (2021)

Thyroid storm following radioactive iodine (RAI) therapy for pediatric graves disease
por: Rohrs, Henry J., et al.
Publicado: (2014)

A Case for Lithium Pretreatment Prior to Radioactive Iodine Ablation in Grave’s Disease
por: Thakkar, Aditi, et al.
Publicado: (2021)

FRI494 Ischemic Stroke After Radioactive Iodine Therapy In Graves Disease
por: Rave, Talia, et al.
Publicado: (2023)

A False Positive I-131 Metastatic Survey Caused by Radioactive Iodine Uptake by a Benign Thymic Cyst
por: Singh, Avneet K., et al.
Publicado: (2017)

Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer
por: Iwano, Shingo, et al.
Publicado: (2020)

The influence of thionamides on intra-thyroidal uptake of (131)I during radioiodine-131 treatment of Graves’ disease
por: Happel, Christian, et al.
Publicado: (2023)

Subclinical Hypothyroidism after (131)I-Treatment of Graves’ Disease: A Risk Factor for Depression?
por: Yu, Jing, et al.
Publicado: (2016)

Duration of antithyroid drug treatment may predict weight gain after radioactive iodine therapy in patients with Graves’ disease
por: Yotsapon, Thewjitcharoen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p05cqj5uqpcfrp48cbrn60osi2